# US 2019/0314452 A1 · Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314452 A1
- Document ID: US20190314452A1
- Status: Published application
- Kind: A1
- Application number: 16/348,249
- Filed: 2017-11-10
- Published: 2019-10-17
- Earliest claimed: 2016-11-10
- Assignees: Yuhan Corporation
- Applicants: Yuhan Corporation
- Inventors: Han Na HONG; Jun Hwan KIM; Hyun Ho CHOI; Dohoon KIM; Taewang KIM; Se Woong OH; Moo Young SONG; Jong Gyun KIM
- Web page: https://patentgrep.com/patent/US20190314452A1

## CPC

- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1703: {from vertebrates}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/20: Interleukins [IL]
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for preventing or treating hepatitis, hepatic fibrosis, or hepatic cirrhosis, which comprises administering to a subject in need thereof a pharmaceutical composition comprising a fusion protein, said fusion protein comprising a fibroblast growth factor 21 (FGF21) mutant protein and an Fc region of an immunoglobulin linked to the FGF21 mutant protein,
wherein the FGF21 mutant protein comprises at least one mutation selected from the group consisting of the following mutations (1) to (7):
(1) a substitution of amino acids at positions 98 to 101 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of EIRP (SEQ ID NO: 68);
(2) a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAV (SEQ ID NO: 69);
(3) a substitution of amino acids at positions 170 to 174 from the N-terminus of a wild-type FGF21 protein with an amino acid sequence of TGLEAN (SEQ ID NO: 70);
(4) a substitution of an amino acid at position 170 from the N-terminus of a wild-type FGF21 protein with an amino acid N;
(5) a substitution of an amino acid at position 174 from the N-terminus of a wild-type FGF21 protein with an amino acid N;
(6) a substitution of an amino acid at position 180 from the N-terminus of a wild-type FGF21 protein with an amino acid E, along with one or more mutations (1) to (5) above; and
(7) a mutation of 1 to 10 amino acids for reducing immunogenicity of a wild-type FGF21 protein.

### Claim 24 (depends on 23)

The method of claim 23, wherein the fusion protein further comprises a biologically active protein, or a mutant or fragment thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein one or more of the amino acid residue N of the FGF21 mutant protein introduced by the mutation of one or more of (3)-(6) are glycosylated.

### Claim 26 (depends on 24)

The method of claim 24, wherein the biologically active protein is one selected from the group consisting of insulin, C-peptide, leptin, glucagon, gastrin, gastric inhibitory polypeptide (GIP), amylin, calcitonin, cholecystokinin, peptide YY, neuropeptide Y, bone morphogenetic protein-6 (BMP-6), bone morphogenetic protein-9 (BMP-9), oxyntomodulin, oxytocin, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), irisin, fibronectin type III domain-containing protein 5 (FNDC5), apelin, adiponectin, C1q and tumor necrosis factor related protein (CTRP family), resistin, visfatin, omentin, retinol binding protein-4 (RBP-4), glicentin, angiopoietin, interleukin-22 (IL-22), exendin-4, and growth hormone.

### Claim 27 (depends on 26)

The method of claim 26, wherein the biologically active protein is one selected from GLP-1, a mutant thereof, and exendin-4.

### Claim 28 (depends on 27)

The method of claim 27, wherein the mutant of GLP-1 has the amino acid sequence of any one of SEQ ID NOs: 43 to 46.

### Claim 29 (depends on 23)

The method of claim 23, wherein the wild-type FGF21 protein has the amino acid sequence of SEQ ID NO: 1.

### Claim 30 (depends on 23)

The method of claim 23, wherein the FGF21 mutant protein has the amino acid sequence represented by any one of SEQ ID NOs: 6 to 23.

### Claim 31 (depends on 23)

The method of claim 23, wherein the fusion protein further comprises a linker.

### Claim 32 (depends on 31)

The method of claim 31, wherein the linker connects the FGF21 mutant protein to the Fc region of the immunoglobulin.

### Claim 33 (depends on 32)

The method of claim 32, wherein one end of the linker is connected to the C-terminus of the Fc region of the immunoglobulin and the other end of the linker is connected to the N-terminus of the FGF21 mutant protein.

### Claim 34 (depends on 32)

The method of claim 32, wherein the linker is a peptide consisting of 10 to 30 amino acid residues.

### Claim 35 (depends on 34)

The method of claim 34, wherein the linker has the amino acid sequence of any one of SEQ ID NOs: 2 to 5.

### Claim 36 (depends on 23)

The method of claim 23, wherein the Fc region of the immunoglobulin is any one of the Fc region of IgG1, IgG2, IgG3, IgG4 and IgD, or a hybrid Fc containing a combination thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hybrid Fc comprises an IgG4 region and an IgD region.

### Claim 38 (depends on 24)

The method of claim 24, wherein the fusion protein comprises the biologically active protein, the Fc region of the immunoglobulin and the FGF21 mutant protein, connected in this order from the N-terminus to the C-terminus.

### Claim 39 (depends on 38)

The method of claim 38, wherein a linker is additionally connected between the Fc region of the immunoglobulin and the FGF21 mutant protein.

### Claim 40 (depends on 39)

The method of claim 39, wherein the linker is connected to the C-terminus of the Fc region of the immunoglobulin and the N-terminus of the FGF21 mutant protein.

### Claim 41 (depends on 23)

The method of claim 23, wherein the fusion protein is represented by any one of the amino acid sequences selected from SEQ ID NOs: 36, 37 and 39.

### Claim 42 (depends on 24)

The method of claim 24, wherein the fusion protein is represented by any one of the amino acid sequences selected from SEQ ID NOs: 65, 66 and 67.
